$XRAY

Dentsply Sirona (XRAY) reported Q2 2026 net sales of $898M, down 4.1% YoY, but swung to a $37M profit from a $45M loss. Adjusted EPS was $0.52, down 1.6% YoY. Margins improved, and cash flow tripled. The company repurchased 1.3M shares and expanded a partnership. Sales declined in most segments, with Orthodontic and Implant Solutions down 13.2%. Full-year guidance was reiterated. Hedge fund ownership fell, and short interest is high at 11.01% of float. Shares trade at a forward P/E of 6.97.

Dentsply Sirona (XRAY) reported 98.5% implant survival and 95.6% success rate for its PrimeTaper EV system in a one-year study. The study, conducted across five international centers, showed progressive stability and minimal bone changes. The company highlights its commitment to evidence-based dentistry and extensive research.

Dentsply Sirona (XRAY) reported Q2 2026 revenue of $898 million, down 4.1% reported (6.3% constant currency). Adjusted EPS was $0.52. Tariff refunds were $44 million, aiding operating cash flow of $99 million. Full-year revenue guidance was maintained at $3.5 to $3.6 billion and adjusted EPS at $1.40 to $1.50.

Dentsply Sirona (NASDAQ:XRAY) reported Q2 segment sales declines amid uneven regional demand and higher operating expenses, including an $8 million FX headwind. Connected Technology Solutions sales were $239M, down 1.5%. Orthodontic and Implant Solutions revenue fell 13.2% to $197M. The company maintained 2026 net sales guidance of $3.5B to $3.6B and adjusted EPS of $1.40 to $1.50.

Dentsply Sirona (XRAY) shares fell about 7% after the company reported Q2 2026 results. Revenue declined 4.1% to $898 million and topped expectations, while adjusted EPS of $0.52 beat estimates. The stock dropped on a weaker full-year revenue forecast of $3.55 billion at the midpoint, about 1% below consensus.

Dentsply Sirona (XRAY) reported Q2 2026 adjusted EPS of 52 cents, down 1.6% YoY but above the Zacks Consensus estimate of 36 cents. Revenue fell 4.1% to $898 million. Wellspect Healthcare growth helped offset declines in other dental segments. The company kept 2026 net sales guidance at $3.5B-$3.6B and adjusted EPS at $1.40-$1.50.

Dentsply Sirona (NASDAQ:XRAY) reported Q2 CY2026 revenue of $898 million, down 4.1% year over year but 0.6% above market expectations. Full-year revenue guidance is $3.55 billion at the midpoint, about 1% below analysts’ estimates. Non-GAAP EPS was $0.52, 50.1% above consensus. Shares rose 1.8% to $13.42 after the release.

DENTSPLY SIRONA (XRAY) said Medline Sinclair will expand distribution of its full technology portfolio across Canada starting Sept. 1, 2026, broadening a prior consumables-focused partnership. The company expects this could help scale digital dentistry solutions. Investors also look to its Aug. 6 Q2 2026 results and guidance on transformation spending and demand pressures.

Dentsply Sirona (XRAY) will report Q2 results Thursday after market hours. The company previously reported $880M revenue, flat year over year, and EPS that beat full-year guidance estimates. For the upcoming quarter, analysts expect revenue to fall 4.6% y/y. The article cites an average analyst price target of $13.44 versus $14.25 current.

Morningstar’s weekly update for the week ended July 17 reported the Morningstar US Market Index down 1.53%, with energy up 4.54% and technology down 3.65%. S&P 500 fell 1.55% and Nasdaq 2.9%. PayPal (PYPL) rose 22.13% while Sandisk (SNDK) fell 29.31%. WTI crude rose to $82.54.